| Literature DB >> 25114547 |
Ravi Bhargava1, Gabriele Hahn2, Wolfgang Hirsch3, Myung-Joon Kim4, Hans-Joachim Mentzel5, Oystein E Olsen6, Eira Stokland7, Fabio Triulzi8, Elida Vazquez9.
Abstract
Magnetic resonance imaging (MRI), frequently with contrast enhancement, is the preferred imaging modality for many indications in children. Practice varies widely between centers, reflecting the rapid pace of change and the need for further research. Guide-line changes, for example on contrast-medium choice, require continued practice reappraisal. This article reviews recent developments in pediatric contrast-enhanced MRI and offers recommendations on current best practice. Nine leading pediatric radiologists from internationally recognized radiology centers convened at a consensus meeting in Bordeaux, France, to discuss applications of contrast-enhanced MRI across a range of indications in children. Review of the literature indicated that few published data provide guidance on best practice in pediatric MRI. Discussion among the experts concluded that MRI is preferred over ionizing-radiation modalities for many indications, with advantages in safety and efficacy. Awareness of age-specific adaptations in MRI technique can optimize image quality. Gadolinium-based contrast media are recommended for enhancing imaging quality. The choice of most appropriate contrast medium should be based on criteria of safety, tolerability, and efficacy, characterized in age-specific clinical trials and personal experience.Entities:
Keywords: contrast-enhanced; expert consensus; gadobutrol; gadolinium; magnetic resonance imaging; pediatrics
Year: 2013 PMID: 25114547 PMCID: PMC4089734 DOI: 10.4137/MRI.S12561
Source DB: PubMed Journal: Magn Reson Insights ISSN: 1178-623X
Applications of pediatric MRI by body region.
| BODY REGION | APPLICATIONS OF MRI | ADVANTAGES OF MRI | MR PROTOCOL |
|---|---|---|---|
| Brain and spine |
–Tumors (eg, ependymoma, medulloblastoma, cerebellar low-grade astrocytoma) – Congenital malformations – Demyelinating diseases – Neurodegenerative disease – Inflammatory diseases – Epilepsy | Extensive experience of anatomic and functional characterization of CNS pathologies | Brain: axial T2-weighted, coronal FLAIR, and coronal and sagittal T1-weighted images |
| Chest |
–Pulmonary diseases of alveolar infiltration or exudation patterns (eg, segmental pneumonia or bronchopneumonia, pulmonary edema) – Tumors – Interstitial pulmonary diseases, fibrotic processes – Lung malformations | Superior visualization of interstitial processes, inflammatory disease | T2-weighted (turbo spin echo) |
| Cardiovascular system |
–Congenital malformations (eg, shunts, fistulae, regurgitant valves) | Provision of 3D anatomic and hemodynamic information, beyond echocardiography and catheterization | Breath-held, ECG-gated, balanced steady-state free precession (b-SSFP) cine image |
| Abdomen |
– Acute abdomen – Unexplained abdominal pain – Appendicitis – Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) – Motility disorders – Congenital GI malformations, eg, biliary atresia, cloacal malformations – GI tumors – Pancreatitis – Ovarian pathology – Trauma | Anatomic depiction of complete abdominal organ systems | Coronal T2-weighted or STIR images in combination with axial T2-weighted and/or fat suppressed (STIR) T2-weighted images |
| Musculoskeletal system |
–Skeletal, congenital, and developmental disorders (eg, hip dysplasia, Meyer’s dysplasia) – Rheumatic diseases (eg, juvenile spondyloarthropathies) – Trauma (bone fracture, tendon, and muscle) – Bone tumors (benign, malignant) – Soft tissue masses (eg, vascular malformations, cysts, fibromatous tumors, neurofibromas, soft tissue malignancies) | Versatile depiction of bone marrow, cartilage, joints, and soft tissues to identify and localize pathology | T1-weighted, T2-weighted, and proton density sequences (at least one combined with fat saturation), short tau inversion recovery sequence |
| Genitourinary tract (urography) |
– Congenital anatomic abnormalities – Vesicoureteric reflux – Hydronephrosis – Obstructive uropathy | Evolving technique for generating high-quality anatomic scans (kidneys, ureters, and bladder) and renal function assessments (eg, split renal function and drainage) | T2-weighted imaging (static-fluid MR urography) |
| Infections | CNS
– Bacterial intracranial infection (eg, epidural and subdural empyema, meningitis, pyogenic abscess) – Spinal infection (eg, spondylodiscitis, epidural abscess) – Viral meningoencephalitis (eg, herpes simplex virus) – HIV – Musculoskeletal (eg, osteomyelitis) – Gastrointestinal (eg, cholangitis) – Vascular (eg, vasculitis) | Sensitive and specific imaging, providing early diagnosis | T1- (pre- and post-gadolinium) and T2-weighted images |
| Metabolic disorders and malformations |
–Stroke (arterial, venous, hemorrhagic) –Hypoxic–ischemic brain injury –Hereditary metabolic diseases (eg, peroxisomal disorders, lysosomal storage disorders, disorders of amino acid and organic acid metabolism) –Brain malformations –Vascular malformations | Depiction of small/subtle pathology | Axial T2-weighted turbo spin echo, an axial FLAIR, T2*-weighted gradient-echo sequences, diffusion-weighted imaging and sagittal T1-weighted acquisition |
| Whole body |
–Tumors –Multifocal lesions (eg, metastases, storage disorders, soft tissue disorders, multifocal osteomyelitis) –Fever of unknown origin –Non-accidental trauma | 3D-anatomic visualization for determining location and extent of lesions; functional/quantitative capabilities | STIR or fat suppressed T2 spin echo, diffusion-weighted imaging, fat suppressed T1 spin echo, 3D-spoiled gradient echo sequences in arterial or portovenous phase following gadolinium contrast, fat suppressed T1 SE (post-gadolinium) |
Figure 7Child with Crohn’s disease with inflamed terminal ileum and inflamed duodenum demonstrated by MR contrast-enhanced enterography. HASTE (A) axial images show thickening of the wall of the distal ileum (arrow) that is slightly brighter than muscle. The T1 transverse images pre- (B) and post-contrast (C) show diffuse enhancement of the thickened wall along with prominence of the vascularity in the adjacent mesentery. This is also seen in the coronal T1 contrast-enhanced images with fat saturation (arrow, D and E), along with similar abnormal enhancement of the thickened duodenal wall (dashed arrow, E and F). Courtesy Professor R Bhargava.
Figure 615 year old with aortic and superior mesenteric artery stenosis secondary to neurofibromatosis. Maximal intensity projections of the subtracted contrast-enhanced VIBE sequences show focal narrowing of the abdominal aorta (arrow) at the level of the renal arteries in coronal (A) and sagittal (B) projections. The sagittal image also shows focal narrowing of the origin of the superior mesenteric artery, just caudal to the normal-sized celiac axis and cranial to the aortic narrowing. Courtesy Professor R Bhargava.
Figure 1Choroid plexus carcinoma of right ventricle, in 2-year-old girl with Turner syndrome, polycystic kidney, nephrolithiasis, and posttraumatic skull fracture with cephalohematoma over right hemisphere. Technique: head coil, 1.5 T, gadobutrol 1 mL by manual injection. Protocol: FLAIR, T2 TSE, T1, T1 Gd. Slice thickness 3–4 mm. Findings: Pre-contrast T2-weighted (B, C, D) and FLAIR (A) images showed a brain tumor with inhomogeneous signal in right ventricle. Surrounding parenchyma of the right hemisphere showed bright signal in T2. Post-contrast (F, G, H): inhomogeneous enhancement in the tumor with cystic changes compared with pre-contrast images (E). Conclusions: MRI provided differential diagnosis of plexus carcinoma vs. plexus papilloma. Courtesy Dr G Hahn.
Figure 2Hemangioma in 7-month-old girl with large soft tissue mass in forehead. Technique: head coil, 1.5 T, gadobutrol 0.6 mL by manual injection. Protocol: T2, T1, T1 Gd. Slice thickness 1.2–3.0 mm. Findings: 3 × 4 × 2 cm tumor attached to the bony calvarium on left side on T2-weighted images (A, B). Intermediate signal on T1 (C) with small spots of higher signal and small tubular hypointensities (signal voids) within the mass. After administration of gadobutrol, the tumor enhanced uniformly, except for central vascular structures (D). No obvious intracranial extension or other pathologic findings. Conclusions: MRI with gadolinium enhancement was valuable for determining the extent of disease and associated anomalies and for excluding malformations of the brain. Courtesy Dr E Stokland.
Practical suggestions for pediatric MRI: equipment and protocol.
| TECHNICAL RECOMMENDATIONS |
|---|
|
Select protocol sequences and parameters on a patient-by-patient basis Use the smallest coil possible to maximize SNR Minimize the examination time Perform the most critical sequences first Key sequences: T1/T2, fast spin echo, gradient echo, FLAIR/STIR/diffusion Slice thickness: Brain: <1-year-old: 3–4 mm, school-age children: 4–5 mm Orbits: 2–3 mm Spine: 3 mm Pituitary: 2–3 mm Body: 4–6 mm Musculoskeletal system: 3–5 mm Angiographic sequences: 1–2 mm Keep voxel size large enough for adequate SNR |
|
|
|
|
|
Use ear plugs or headphones to protect the patient’s ears Apply anesthetic cream to reduce pain at venipuncture site Encourage natural sleep to reduce anxiety and movement Sedation/GA, if required, should follow local guidelines An adult family member should accompany the child during the scan |
Abbreviations: FLAIR, fluid-attenuated inversion-recovery; GA, general anesthesia; MRI, magnetic resonance imaging; SNR, signal-to-noise ratio; STIR, short inversion-time inversion recovery; T, Tesla.
Properties and approval status of extracellular gadolinium-based contrast agents.a
| CHEMICAL NAME | TRADE NAME | MANUFACTURER | CHARGE AND CHEMICAL STRUCTURE | CONCENTRATION (mol/L) | KINETIC STABILITY | RELAXIVITY (3 T IN PLASMA, 37°C) [L/mmol−1s−1] | T1 SHORTENING TIME (MS) IN BLOOD FOR 1 mL/L AGENT | VISCOSITY [mPa*s] | OSMOLALITY [mOsm/kg H2O] | EXCRETION | RECOMMENDED DOSES FOR IMAGING (mmol/kg) | APPROVED DOSES FOR CHILDREN (mmol/kg) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gadodiamide | Omniscan | GE Healthcare | Nonionic linear | 0.5 | 35 s | 4.0 | 880.85 | 1.4 | 790 | Renal | Body 0.1 | From 2 years: 0.1 |
| Gadopentetate dimeglumine | Magnevist | Bayer | Ionic linear | 0.5 | 10 min | 3.7 | 864.80 | 2.9 | 1960 | Renal | CNS 0.1 | From 2 years: 0.1 |
| Gadobenate dimeglumine | MultiHance | Bracco | Ionic linear | 0.5 | N/A | 5.5 | 960.96 | 5.3 | 1970 | Renal, 4–5% hepatobiliary | CNS 0.1 | From 2 years: 0.1 |
| Gadoversetamide | OptiMARK | Tyco | Nonionic linear | 0.5 | N/A | 4.5 | N/A | 2.0 | 1110 | Renal | CNS 0.1 | Not approved <18 years |
| Gadoterate meglumine | Dotarem | Guerbet | Ionic cyclic | 0.5 | >1 month | 3.5 | 859.0 | 2.0 | 1350 | Renal | CNS 0.1 | Infants and children: 0.1 |
| Gadoteridol | ProHance | Bracco | Nonionic cyclic | 0.5 | 3 h | 3.7 | 870.33 | 1.3 | 630 | Renal | CNS 0.1 | From 2 years: 0.1 |
| Gadobutrol | Gadovist, Gadavist | Bayer | Nonionic cyclic | 1.0 | 24 h | 5.0 | 1036.96 | 4.96 | 1390 | Renal | CNS 0.1 | From 2 years: 0.1 |
| Gadoxetic acid | Primovist | Bayer | Ionic linear | 0.5 | N/A | 6.2 | N/A | 1.19 | 668 | 50% renal, 50% hepatobiliary | Liver 0.025 | Not approved <18 years |
Please consult your local prescribing information for the latest information on approved indications and dosing.
Kinetic stability: dissociation half-life at pH 1.0.
Figure 3Comparative rates of gadolinium ion release for 1 molar solutions of gadolinium-based contrast media in serum from healthy volunteers at 37°C. Reproduced from Thomas Frenzel, Philipp Lengsfeld, Heiko Schirmer, Joachim Hütter, Hanns-Joachim Weinmann, Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C, Invest Radiol, 2008;43:817–828 with permission from Wolters Kluwer Health.
Gadolinium-based contrast media classified according to CHMP categorization of NSF risk (CHMP 2009).80
|
|
Abbreviations: CHMP, Committee for Medicinal Products for Human Use; NSF, nephrogenic systemic fibrosis.
Figure 4Simulated gadolinium concentrations in plasma 20 minutes after injection of 0.1 mmol/kg body weight gadobutrol in four subjects of different ages represented by typical body weight. Boxes represent interquartile range, with the center horizontal line at median. Whiskers extend to data nearest to a distance of at most 1.5 times the interquartile range. Reproduced from Gabriele Hahn, Ina Sorge, Bernd Gruhn, Katja Glutig, Wolfgang Hirsch, Ravi Bhargava, Julia Furtner, Mark Born, Cronelia Schroder, Hakan Ahlstrom, Sylvie Kaiser, Jorg Detlev Moritz, Christian Wilhelm Kunze, Manohar Shroff, Eira Stokland, Zuzana Jirakova Trnkova, Marcus Schultze-Mosgau, Stefanie Reif, Claudia Bacher-Stier, Hans-Joachim Mentzel, Pharmacokinetics and Safety of Gadobutrol-Enhanced Magnetic Resonance Imaging in Pediatric Patients, Invest Radiol, 2009;44:776–783 with permission from Wolters Kluwer Health.
Figure 5Neurofibromatosis type II diagnosed in 15-year-old girl with multiple cutaneous tumors and meningeal tumors. Technique: head coil, 1.5 T, Gd (gadopentetate dimeglumine or gadobutrol) by manual injection. Protocol: T2 TSE, T1, T1 Gd. Slice thickness 3–5 mm. Transverse (A, T1; B, T1 Gd), coronal (C, T1 Gd), and sagittal views (D, T2; E, T1; F and G, T1 Gd with gadopentetate dimeglumine and gadobutrol, respectively). Findings: Strong contrast enhancement in internal auditory canal. A high relaxivity agent (gadobutrol, 5 ml) showed strong enhancement in the cervical myelon (G vs. F). Conclusions: MRI assisted to diagnose schwannoma of the vestibular nerve at both hemispheres and also intraspinal neurofibroma. Notably, gadobutrol provided greater imaging efficacy than gadopentetate dimeglumine. Courtesy Professor H-J Mentzel.
Practical suggestions for pediatric MRI: contrast medium use.
|
Use of gadolinium-containing contrast media should not be a problem in patients with normal renal function according to age Base dose on the child’s weight, not age Weight should be measured, not estimated Syringes should allow precise dosing, eg, 1 mL insulin syringes are recommended for young infants Injection technique (manual vs. automated) is age- dependent Contrast injection uses a 22 or 24 gauge needle Prior to injection of contrast, the intravenous line is flushed with saline to clear the line. Contrast of 0.1 mL/kg is injected at a rate of 0.5 mL/sec A saline flush of sufficient volume to clear the intravenous line post-contrast administration should be injected at a rate of 0.5 mL/sec Bolus timing is affected by heart rate, cardiac output, and injection site and is therefore unpredictable. Bolus monitoring is recommended Renal function (ie, estimated glomerular filtration rate) should be determined in patients at risk, such as: Children with known renal disease Children on medication toxic to the kidneys, eg, oncology patients on treatment Children with dehydration Children with complex diseases also affecting the kidneys Children who received iodinated contrast media in the last 24 hours In children with severely reduced renal function, MRI without intravenous contrast or an alternative method should be considered Safety concerns regarding risk/benefit assessment remain the responsibility of the treating clinician and local label indications should be observed |
Abbreviation: MRI, magnetic resonance imaging.